Spearheading the Semantic Web

April 5, 2006 | BOSTON – Sharing their passion for the Semantic Web at the Bio-IT World Life Sciences Conference + Expo session on Tuesday were several prominent leaders of the movement.

Providing a clinical perspective was Tonya Hongsermeier of Partners Healthcare, who said the Semantic Web is necessary for knowledge management because “the market is balking at healthcare inflation.” She said eight datapoints are now kept for each patient (age, height, weight, etc.), but with new tests and personalized medicine, the number could balloon to 3000. The Semantic Web can reduce the cost and liability of knowledge management, said Hongsermeier, and is a critical component of translational medicine going forward.

Eric Miller, Semantic Web lead at the W3C, spoke of the huge growth of interest in recombinant data, which integrates and re-uses data across artificial boundaries. The use of uniform resource identifiers (URIs) in the Semantic Web makes data more machine-readable, freeing it from the application in which it was created to be used in other applications. The use of resource description framework (RDFs) lets users link objects in relational databases that they could not link before.

Explaining the difference between current Web applications and the Semantic Web, Teranode’s Matt Shanahan said the Semantic Web, in effect, adds “lenses” that let you visualize the data in different ways. In addition, Semantic Web applications incorporate multidimensional links, pop-up boxes with related data, and annotations, in contrast to the regular Web’s plain hyperlinks.

There is a great need for data integration in biology, said Teranode’s Eric Neumann, and the Semantic Web provides the flexibility to “plan for change.” He stressed the importance of the power of links – the “network effect” that the Semantic Web provides, as well as the lower reliance on complex middleware. Within a Semantic Web framework, data is not a string, but a URI, and using the same URIs lets you “stitch together” different data from different sources.

Oracle’s Susie Stephens and Northeastern University’s Ken Baclawski offered a programming perspective. Stephens touched on the importance of RDFs, which she said are complementary to Oracle’s databases. Baclawski addressed the question: How can you use the logic-based Semantic Web when a lot of the information you’re searching for is uncertain? The answer, he said, is in Bayesian networks, which are graphical techniques, and graphics is also an important feature of the Semantic Web.

Asked if the Semantic Web was not reminiscent of the hierarchical databases of the 1970s, Stephens agreed that they are similar, but the big difference is today’s computer infrastructure is much more powerful, allowing the Semantic Web to scale.

Related Story:

Jump-Starting Semantic Web Efforts

 



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .